港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,772.232

+40.7992.36%

涨家数：7

跌家数：- -

平家数：1

市盈率：- -

高：1,805.863

开：1,735.522

低：1,735.522

收：1,731.433

数据加载中...

总览新闻资讯

杭州博之锐生物制药有限公司药品申请临床试验默示许可获受理

浙江海昶生物医药技术有限公司药品申请临床试验默示许可获受理

昭衍新药盘中异动早盘大幅拉升5.14%

基石药业PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期临床试验完成首例患者给药

每日经济新闻

港股异动 | 来凯医药-B(02105)再涨近5% 公司自研新药LAE120获美国FDA临床试验批准

智通财经网

联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验

药明生物(02269.HK)推全新微生物表达平台EffiX

阿斯达克财经

基石药业(02616.HK)治疗实体瘤药物临床试验顺利完成首例患者给药

阿斯达克财经

药明生物推出全新微生物表达平台EffiX

基石药业(02616)CS2009全球多中心I期临床试验完成首例患者给药

【基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药】基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。

基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药

联邦制药(03933.HK)UBT251注射液获美FDA批准新药临床试验

阿斯达克财经

联邦制药(03933)研发的UBT251 注射液 CKD 适应症获美国 FDA 批准新药临床试验

康泰生物(300601.SZ)子公司收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告

华东医药(000963.SZ)：多肽类人GLP-1受体和GIP受体的双靶点长效激动剂HDM1005注射液临床试验获批

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1772.232,"timestamp":1741248510306,"preClose":1731.4331,"halted":0,"volume":100037287,"delay":0,"changeRate":0.023564,"change":40.79895,"pbRate":2.648404,"amount":2232823119,"amplitude":0.040626,"prevYearClose":1395.7731,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"turnoverRate":0.00862,"marketCap":380565866496,"floatMarketCap":164754930944,"peRate":33.012456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1805.8632,"amplitude":0.040626,"preClose":1731.4331,"low":1735.5215,"pbRate":"2.648404","latestPrice":1772.232,"volume":100037287,"delay":0,"open":1735.5215,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"sixtyDayClose":1360.467,"secType":"PLATE","market":"HK","turnoverRate":0.00862,"peRate":33.012456,"marketCap":380565866496,"floatMarketCap":164754930944,"timestamp":1741248510306,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516167776","title":"杭州博之锐生物制药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516167776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516167776?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，杭州博之锐生物制药有限公司、浙江博锐生物制药有限公司联合申请药品“注射用BR111”，获得临床试验默示许可，受理号CXSL2400885。通过天眼查大数据分析，杭州博之锐生物制药有限公司参与招投标项目279次，知识产权方面有商标信息4条，专利信息37条，此外企业还拥有行政许可32个。主要股东信息显示，杭州博之锐生物制药有限公司由浙江博锐生物制药有限公司持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","BK1576","BK1583"],"gpt_icon":0},{"id":"2516160536","title":"浙江海昶生物医药技术有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516160536","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516160536?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，浙江海昶生物医药技术有限公司联合申请药品“HC016脂质复合物注射液”，获得临床试验默示许可，受理号CXHL2401413。浙江海昶生物医药技术有限公司，成立于2013年，位于杭州市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，浙江海昶生物医药技术有限公司共对外投资了6家企业，参与招投标项目59次，知识产权方面有商标信息10条，专利信息18条，此外企业还拥有行政许可18个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","161726","03347","399441","BK1583","BK1576"],"gpt_icon":0},{"id":"2516690928","title":"昭衍新药盘中异动 早盘大幅拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690928?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 10:45","pubTimestamp":1741056319,"startTime":"0","endTime":"0","summary":"2025年03月04日早盘10时45分，昭衍新药股票出现异动，股价快速拉升5.14%。截至发稿，该股报13.900港元/股，成交量146.078万股，换手率1.23%，振幅8.17%。机构评级方面，在所有6家参与评级的机构中，67%的券商给予买入建议，17%的券商给予持有建议，16%的券商给予卖出建议。昭衍新药股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，和誉-B、荃信生物-B、科笛-B涨幅较大，振幅较大的相关个股有科笛-B、北海康成-B、和誉-B，振幅分别为12.21%、12.14%、11.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030410451996386f36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030410451996386f36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2516690737","title":"基石药业PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690737","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690737?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 10:43","pubTimestamp":1741056197,"startTime":"0","endTime":"0","summary":"每经AI快讯，基石药业今日宣布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，进而推动肿瘤免疫疗法的创新与发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335813894.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335813894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1583","BK4023","03347","LU1169590202.USD","BK1141","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2516558697","title":"港股异动 | 来凯医药-B(02105)再涨近5% 公司自研新药LAE120获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516558697","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516558697?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 10:23","pubTimestamp":1741054980,"startTime":"0","endTime":"0","summary":"来凯医药-B再涨近5%，截至发稿，涨4.85%，报13.4港元，成交额3360.26万港元。消息面上，来凯医药昨日宣布，美国食品药品监督管理局已批准其自主研发的LAE120，一种强效、高选择性USP1抑制剂的新药临床试验申请，用于治疗晚期实体瘤患者。公司表示正积极开展外部合作以加快LAE120临床开发进展。来凯医药首席执行官吕向阳博士表示，来凯又一款早期研发项目获批IND，体现了来凯在新药研发领域的实力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-04/doc-inenncvp9980225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02105","BK1576","BK1161","BK1583","BK1141","03347"],"gpt_icon":0},{"id":"2516912266","title":"联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2516912266","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516912266?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 09:31","pubTimestamp":1741051903,"startTime":"0","endTime":"0","summary":"3月4日，联邦制药（03933）发布公告，近日公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局（FDA）批准，允许开展慢性肾脏病（CKD）适应症的II期临床试验。此前，该适应症已于2025年1月20日获得中国国家药品监督管理局的临床试验批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335652766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1574","06978","BK1576","BK1191","03347","BK1161","03933","BK1583"],"gpt_icon":0},{"id":"2516699110","title":"药明生物(02269.HK)推全新微生物表达平台EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516699110","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516699110?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 09:18","pubTimestamp":1741051080,"startTime":"0","endTime":"0","summary":"药明生物宣布推出创新技术平台EffiX，该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA，通过提供全面且具有成本效益的CMC策略，简化工艺开发流程，可以满足从研究到商业化生产的各种项目服务需求，协助全球合作伙伴加速研发创新生物疗法。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421839/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0588546209.SGD","LU0039217434.USD","LU0456827905.SGD","LU0516422952.EUR","SG9999002463.SGD","LU1794554557.SGD","LU0181495838.USD","LU0516422440.USD","LU0052750758.USD","LU0823426480.USD","LU1688375341.USD","SG9999002562.SGD","LU0516423174.USD","LU0819121731.USD","LU2039709279.SGD","LU0348735423.USD","02269","LU0456846285.SGD","LU0359201612.USD","LU0327786744.USD","LU0043850808.USD","LU0979878070.USD","LU1242518857.USD","LU0516422366.SGD","BK1141","LU0307460666.USD","LU0516423091.SGD","LU0572944931.SGD","LU0359202008.SGD","LU0417516738.SGD","BK1521","LU0051755006.USD","LU0417516902.SGD","LU1720050803.USD","BK1576","IE00B0JY6N72.USD","LU0856984785.SGD","BK1589","BK1610","LU0320764599.SGD","LU0348825331.USD","LU0823426308.USD","LU0140636845.USD","LU1880383366.USD","LU1242518931.SGD","LU0326950275.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2516361696","title":"基石药业(02616.HK)治疗实体瘤药物临床试验顺利完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516361696","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516361696?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 09:00","pubTimestamp":1741050000,"startTime":"0","endTime":"0","summary":"基石药业公布，其自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。临床前研究显示，CS2009的抗肿瘤活性优于潜在竞品。(港股报价延迟最少十五分钟。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421823/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1141","02616","BK1576","BK1583","BK1574","03347"],"gpt_icon":0},{"id":"2516869507","title":"药明生物推出全新微生物表达平台EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516869507","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516869507?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 08:48","pubTimestamp":1741049328,"startTime":"0","endTime":"0","summary":"【药明生物推出全新微生物表达平台EffiX】药明生物（02269.HK）今日宣布，推出创新技术平台EffiXTM。该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202503043335398947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456827905.SGD","LU0516422952.EUR","LU0979878070.USD","BK1610","LU1794554557.SGD","BK1141","LU0823426480.USD","LU0327786744.USD","LU0181495838.USD","LU0359201612.USD","BK1521","LU0856984785.SGD","LU0326950275.SGD","LU0348735423.USD","LU0588546209.SGD","LU0051755006.USD","IE00B0JY6N72.USD","02269","LU0307460666.USD","LU1242518931.SGD","LU0819121731.USD","BK1576","LU0052750758.USD","LU0823426308.USD","LU2039709279.SGD","LU0320764599.SGD","BK1589","SG9999002463.SGD","LU1880383366.USD","LU1242518857.USD","LU0348825331.USD","LU0043850808.USD","LU0456846285.SGD","LU0572944931.SGD","LU0708995583.HKD","LU1720050803.USD","LU0140636845.USD","LU1688375341.USD","LU0516422366.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0516423091.SGD","LU0039217434.USD","LU0516422440.USD","LU0516423174.USD","LU0417516738.SGD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2516269575","title":"基石药业(02616)CS2009全球多中心I期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269575","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269575?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 08:47","pubTimestamp":1741049275,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业(02616)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954249","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","03347","BK1583","BK1161","BK1574","BK1141","BK1576"],"gpt_icon":0},{"id":"2516984776","title":"【基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药】基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516984776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516984776?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047048,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04081048500557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1169589451.USD","BK4023","BK1141","PD","BK1161","02616","BK1574","03347","BK1576","LU1169590202.USD","BK1583"],"gpt_icon":0},{"id":"2516698610","title":"基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698610","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516698610?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 08:06","pubTimestamp":1741046794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。目前，CS2009率先在澳大利亚开展多中心I期临床试验，未来将陆续扩展至中国及美国。据悉，CS2009是一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，作为靶向大瘤种的三特异性抗体，具备同类首创/同类最优潜力。临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03347","BK1576","BK1161","BK1141","BK1574","LU1169590202.USD","02616","LU1169589451.USD","BK4023","PD"],"gpt_icon":0},{"id":"2516250655","title":"联邦制药(03933.HK)UBT251注射液获美FDA批准新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2516250655","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516250655?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 00:35","pubTimestamp":1741019700,"startTime":"0","endTime":"0","summary":"联邦制药(03933.HK) 公布，全资附属联邦生物科技(珠海横琴)自主研发的1类创新药UBT251注射液获美国药品监督管理局“FDA”许可，同意开展慢性肾脏病“CKD”适应症II期临床试验。此前，CKD适应症已获得中国国家药品监督管理局临床试验批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421743/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","BK1191","BK1576","03933","BK1583","03347"],"gpt_icon":0},{"id":"2516631305","title":"联邦制药(03933)研发的UBT251 注射液 CKD 适应症获美国 FDA 批准新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631305","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631305?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 22:18","pubTimestamp":1741011490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 公布，近日，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液获得美国药品监督管理局许可，同意开展慢性肾脏病适应症 II 期临床试验。此前，CKD 适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前，成人 2 型糖尿病、超重或肥胖、CKD 等多个适应症已取得中国及美国两地药物临床试验批准，并已于中国率先进入临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03933","BK1576","BK1191","BK1583","03347"],"gpt_icon":0},{"id":"2516898026","title":"康泰生物(300601.SZ)子公司收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2516898026","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516898026?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 18:28","pubTimestamp":1740997699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(“民海生物”)近日收到吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告，民海生物研发的吸附破伤风疫苗临床研究阶段工作顺利完成。研究结果显示，民海生物研制的吸附破伤风疫苗应用于成人免疫具有良好的安全性和免疫原性。本次吸附破伤风疫苗Ⅰ/Ⅲ期临床试验总结报告的取得表明吸附破伤风疫苗具备了申报生产的必备条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0201","BK0239","BK1583","03347","159646","300601","BK1141","BK0046"],"gpt_icon":0},{"id":"2516856686","title":"华东医药(000963.SZ)：多肽类人GLP-1受体和GIP受体的双靶点长效激动剂HDM1005注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2516856686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516856686?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 17:47","pubTimestamp":1740995243,"startTime":"0","endTime":"0","summary":"据悉，HDM1005注射液是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类化学新药，是多肽类人GLP-1受体和GIP受体的双靶点长效激动剂。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，GLP-1类产品具有减肥、降糖和心血管获益等作用，是相对成熟和安全的靶点。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","LU1969619763.USD","03347","BK4590","BK0175","000963","BK0188","BK4144","BK1141","BK0209","BK0196","GLP","BK1576","BK0183","BK0187","LU2328871848.SGD","BK1583"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":5,"totalSize":219}]}}